CDK4 and breast carcinoma: Endocrine therapy, usually with an aromatase inhibitor in post-menopausal females, combined with a CDK4/6 inhibitor is the first-line treatment for advanced breast cancer positive for estrogen and/or progesterone (ER+/PR+) hormone receptor and HER2- overexpression [6].